









Markets
/
Stocks
/
nasdaq-uncy
/

Unicycive Therapeutics Inc

UNCY



View Detailed Chart

5.400USD

+0.130+2.47%

Close 11/21, 16:00（ET）Quotes delayed by 15 min

112.59MMarket Cap

LossP/E TTM



Unicycive Therapeutics Inc

5.400

+0.130+2.47%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+2.47%

5 Days

-4.76%

1 Month

+9.31%

6 Months

+847.37%

Year to Date

+579.93%

1 Year

+923.11%

View Detailed Chart

TradingKey Stock Score of Unicycive Therapeutics Inc

Currency: USD Updated: 2025-11-21

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Unicycive Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

156 / 406

Overall Ranking

260 / 4593

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

52.250

Target Price

+891.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Unicycive Therapeutics Inc Highlights

StrengthsRisks

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -1.55, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.54M shares, decreasing 25.65% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 658.88K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.